212 related articles for article (PubMed ID: 9394854)
1. Anastrozole--a new generation in aromatase inhibition: clinical pharmacology.
Dowsett M; Lønning PE
Oncology; 1997; 54 Suppl 2():11-4. PubMed ID: 9394854
[TBL] [Abstract][Full Text] [Related]
2. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.
Geisler J; King N; Dowsett M; Ottestad L; Lundgren S; Walton P; Kormeset PO; Lønning PE
Br J Cancer; 1996 Oct; 74(8):1286-91. PubMed ID: 8883419
[TBL] [Abstract][Full Text] [Related]
3. Effects of the aromatase inhibitor anastrozole on serum oestrogens in Japanese and Caucasian women.
Dowsett M; Donaldson K; Tsuboi M; Wong J; Yates R
Cancer Chemother Pharmacol; 2000; 46(1):35-9. PubMed ID: 10912575
[TBL] [Abstract][Full Text] [Related]
4. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.
Geisler J; Haynes B; Anker G; Dowsett M; Lønning PE
J Clin Oncol; 2002 Feb; 20(3):751-7. PubMed ID: 11821457
[TBL] [Abstract][Full Text] [Related]
5. A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex) with intramuscular formestane in postmenopausal women with advanced breast cancer.
Vorobiof DA; Kleeberg UR; Perez-Carrion R; Dodwell DJ; Robertson JF; Calvo L; Dowsett M; Clack G
Ann Oncol; 1999 Oct; 10(10):1219-25. PubMed ID: 10586340
[TBL] [Abstract][Full Text] [Related]
6. Use of aromatase inhibitors in breast carcinoma.
Santen RJ; Harvey HA
Endocr Relat Cancer; 1999 Mar; 6(1):75-92. PubMed ID: 10732791
[TBL] [Abstract][Full Text] [Related]
7. Are differences in the available aromatase inhibitors and inactivators significant?
Johnson PE; Buzdar A
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4360s-4368s; discussion 4411s-4412s. PubMed ID: 11916226
[TBL] [Abstract][Full Text] [Related]
8. Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.
Miller WR; Stuart M; Sahmoud T; Dixon JM
Br J Cancer; 2002 Oct; 87(9):950-5. PubMed ID: 12434282
[TBL] [Abstract][Full Text] [Related]
9. Endocrine effects of nonsteroidal aromatase inhibitors and their clinical impact.
Bajetta E; Zilembo N; Bichisao E
J Clin Oncol; 2002 Jul; 20(13):3039-40; author reply 3040. PubMed ID: 12089238
[No Abstract] [Full Text] [Related]
10. The relevance of preclinical models to the treatment of postmenopausal breast cancer.
Dukes M
Oncology; 1997; 54 Suppl 2():6-10. PubMed ID: 9394853
[TBL] [Abstract][Full Text] [Related]
11. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
Kijima I; Itoh T; Chen S
J Steroid Biochem Mol Biol; 2005 Dec; 97(4):360-8. PubMed ID: 16263272
[TBL] [Abstract][Full Text] [Related]
12. A randomised comparison of oestrogen suppression with anastrozole and formestane in postmenopausal patients with advanced breast cancer.
Kleeberg UR; Dowsett M; Carrion RP; Dodwell DJ; Vorobiof DA; Aparicio LA; Robertson JF
Oncology; 1997; 54 Suppl 2():19-22. PubMed ID: 9394856
[TBL] [Abstract][Full Text] [Related]
13. Biology of aromatase inhibitors: pharmacology/endocrinology within the breast.
Miller WR
Endocr Relat Cancer; 1999 Jun; 6(2):187-95. PubMed ID: 10731108
[TBL] [Abstract][Full Text] [Related]
14. Aromatase inhibitors: a dose-response effect?
Smith IE
Endocr Relat Cancer; 1999 Jun; 6(2):245-9. PubMed ID: 10731116
[No Abstract] [Full Text] [Related]
15. Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer.
Folkerd EJ; Dixon JM; Renshaw L; A'Hern RP; Dowsett M
J Clin Oncol; 2012 Aug; 30(24):2977-80. PubMed ID: 22802308
[TBL] [Abstract][Full Text] [Related]
16. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.
Buzdar AU; Robertson JF; Eiermann W; Nabholtz JM
Cancer; 2002 Nov; 95(9):2006-16. PubMed ID: 12404296
[TBL] [Abstract][Full Text] [Related]
17. Anastrozole: a selective aromatase inhibitor for the treatment of breast cancer.
Higa GM; alKhouri N
Am J Health Syst Pharm; 1998 Mar; 55(5):445-52. PubMed ID: 9522927
[TBL] [Abstract][Full Text] [Related]
18. Anastrozole (Arimidex)--an aromatase inhibitor for the adjuvant setting?
Buzdar AU
Br J Cancer; 2001 Nov; 85 Suppl 2(Suppl 2):6-10. PubMed ID: 11900212
[TBL] [Abstract][Full Text] [Related]
19. The preclinical pharmacology of "Arimidex" (anastrozole; ZD1033)--a potent, selective aromatase inhibitor.
Dukes M; Edwards PN; Large M; Smith IK; Boyle T
J Steroid Biochem Mol Biol; 1996 Jul; 58(4):439-45. PubMed ID: 8903429
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors.
Buzdar AU
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):468S-72S. PubMed ID: 12538502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
